ProPhase Labs (PRPH)
(Real Time Quote from BATS)
$5.22 USD
+0.17 (3.37%)
Updated May 13, 2024 03:32 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
PRPH 5.22 +0.17(3.37%)
Will PRPH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PRPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PRPH
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates
PRPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
ProPhase Labs, Inc. (PRPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates
Other News for PRPH
ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - Updated
PRPH Stock Earnings: ProPhase Labs Beats EPS, Misses Revenue for Q1 2024
ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives.
ProPhase Labs GAAP EPS of -$0.07 beats by $0.21, revenue of $3.63M misses by $6.23M
ProPhase Labs reports Q EPS (7c) vs. 3c last year